Hair Regrowth Treatment For Women In Weston, FL
Revive 365 Wellness sees women with hair thinning at Weston, FL. Topical minoxidil, in the 2% solution and 5% foam strengths, is the only drug the FDA has approved for female pattern hair loss. Low-dose oral minoxidil and spironolactone are prescribed off-label and have published trial data in women. PRF is your own blood, spun and returned the same visit, and no blood-separation device carries an FDA clearance for the scalp.
In-person and telehealth appointments available
Four different conditions cause hair loss in women, and they need different answers
Thinning hair in a woman is not one diagnosis. It is at least 4, they look similar in a bathroom mirror, and 1 of them causes permanent loss. Working out which one you have comes before any treatment decision, because 2 of these do not respond to the treatments sold for the other 2.
Female pattern hair loss
Gradual. Thinning concentrated over the crown and along the part, which slowly widens. The frontal hairline is usually preserved. Individual hairs get finer and shorter over years rather than coming out in handfuls. This is the condition topical minoxidil is approved to treat.
Clinicians usually describe the severity on the Ludwig scale, which has 3 grades based on how wide the part has become and how much scalp shows through at the crown. Asking which grade you are, and having it written down, gives you a fixed reference point. Hair changes too slowly for memory to be a reliable instrument.
Telogen effluvium
Sudden and diffuse. Hair comes out in the shower and on the pillow, typically 2 to 3 months after a trigger: childbirth, surgery, a crash diet, a high fever, a thyroid change, a new medication, or a significant shock. It usually resolves once the trigger is dealt with.
This is the one most often mistaken for pattern loss, and the mistake runs in an expensive direction. A woman shedding heavily 3 months after a delivery is frequently sold a course of scalp treatment for a condition that was going to settle anyway. The 2 conditions also occur together, which is exactly why a shedding episode is the moment most women first go looking for help.
Central centrifugal cicatricial alopecia
Scarring, and permanent. It begins at the crown and spreads outward. The American Academy of Dermatology describes it as the most common type of scarring hair loss for women of African descent, and states that the first sign is often noticeable hair loss in the center, or crown, of the scalp. Published prevalence figures come from 2 studies: a 2007 British Journal of Dermatology survey of 874 African adults found it in 2.7% of all women surveyed and in 6.7% of women over 50, and a 2011 study of 529 African American women found extensive central scalp hair loss in 5.6%.
Once a follicle is scarred it is gone. No drug regrows it and no injection brings it back.
How unsettled the treatment is may be the most useful thing on this page. In 2024, 27 dermatologists with expertise in hair and scalp disorders ran a 3-round Delphi consensus on CCCA treatment, published in the Journal of the American Academy of Dermatology. Across 70 statements, they reached strong consensus on 20. Fewer than 3 in 10. If the specialists cannot agree on most of the treatment of this condition, a scalp package offered without a diagnosis is not a considered plan.
If your thinning started at the crown and your scalp feels tender, tight, itchy, or burning, that is a dermatologist referral. A biopsy may be needed. Injecting into active scarring disease is the one mistake on this page that cannot be undone.
Alopecia areata
Round, well-defined bald patches. Autoimmune, and it behaves nothing like the other 3.
It is also the only 1 of the 4 with a recent run of new FDA approvals. Baricitinib was approved for severe alopecia areata on June 13, 2022, ritlecitinib on June 23, 2023, and deuruxolitinib on July 25, 2024, reaching the US market on July 14, 2025. All 3 carry a boxed warning covering serious infections, mortality, malignancy, major adverse cardiovascular events, and thrombosis. None of the 3 is approved for female pattern hair loss.
The 3-Rung Rule: how to place any treatment you are offered
Every treatment sold for women’s hair loss sits on 1 of 3 rungs. The rung tells you how much regulatory review it has been through and how much evidence stands behind it for women specifically. Ask which rung before you agree to anything.
Rung 1. FDA-approved for female pattern hair loss
Topical minoxidil, and nothing else. The 2% solution and the 5% foam are approved for women. The 5% solution is approved for men only. There is no other approved drug for this condition, in either sex.
Watch the wording carefully here, because 2 words get used interchangeably and they are not the same. Approved means the FDA reviewed evidence that a drug works for a stated condition. Cleared is a lower bar, applied to devices, meaning the device is similar enough to something already on the market. A laser cap described as “FDA approved” is being described incorrectly.
Rung 2. Off-label or cleared for something else, with published trial evidence
Prescription drugs used for a condition their label does not name, and procedures with published trials but no clearance for this use. This is legal, common, and often reasonable. It requires the person offering it to say so out loud. This rung holds low-dose oral minoxidil, spironolactone, PRF, and microneedling.
Rung 3. No FDA approval, no clearance for this use
Exosome products and products marketed as containing stem cells. Available in clinics across South Florida. Not reviewed by any agency for this purpose.
The rule: do not buy from Rung 3 before Rung 1 is in place. The common pattern in this market is a woman being offered a Rung 2 or Rung 3 package on her first visit without ever being told that a Rung 1 option exists. Sequence is the thing this rule protects.
PRF: what it is, what the research in women shows, and how much of it there is
PRF stands for platelet-rich fibrin, and it is made from your own blood in the room during your visit.
Blood is drawn into a plain tube with nothing added to it. Because no anticoagulant is present, a single low-speed spin lets the platelets and plasma proteins set into a soft fibrin clot, and that clot is the treatment. The fibrin matters. Growth factors stay caught in the mesh and come out gradually over roughly 10 days rather than emptying in the first hour, which a 2016 study in Clinical Oral Investigations measured directly across 7 different growth factors.
One randomized controlled trial of PRF for female pattern hair loss has been published. It appeared in 2026 in the Journal of Dermatological Treatment, ran across multiple centers, and enrolled 74 women with Sinclair grade II to III thinning. Women receiving 4 monthly injectable PRF sessions increased their non-vellus hair count in the target area by 26.54%, with a standard deviation of 11.46%. Hair diameter improved as well, though the improvement in diameter was not statistically distinguishable between the treatment groups. The trial also found a positive correlation between VEGF concentration in the preparation and the increase in hair count.
A second study, published in 2024 in the Journal of Cosmetic and Laser Therapy and run at Queen Mary University of London, followed 11 women with Ludwig grade I to II thinning through 3 injectable PRF sessions at weeks 0, 4 and 8. Hair density rose from 0.57 follicles per square millimeter to 0.89 at 12 weeks and 1.03 at 24 weeks. Pull-test scores and quality-of-life scores both improved. That study had no control group, followed 11 people, and its authors say so.
A third, published in 2025 in Archives of Dermatological Research, followed 30 patients who had responded poorly to conventional treatment through 6 monthly sessions and reported an 80% response rate at 6 months. It was also uncontrolled.
Why most women are not hair transplant candidates
The American Hair Loss Association estimates that approximately 2 to 5% of women with hair loss are potential candidates for surgical hair restoration, against approximately 90 percent of balding men.
The reason is the donor area. A transplant relocates hair, it does not create it. In male pattern loss the back and sides usually stay stable and supply reliable grafts. In female pattern loss the thinning is diffuse, so the donor area is frequently thinning too. Moving fragile hair to the top of the head produces fragile hair on the top of the head.
The surgical data reflects this in a way transplant directories rarely mention. The ISHRS 2025 Practice Census, reporting on 2024 procedures, found that strip harvesting was used in 30.0% of female hair restoration procedures against 12.5% of male procedures, with FUE accounting for 68.2% of female and 85.4% of male procedures. Strip harvesting can take more grafts from a limited safe zone and does not require shaving the donor area. FUE, which is what nearly every transplant page in South Florida advertises, is used far more often in men. ISHRS also reported that the number of female surgical patients treated in 2024 rose 16.5% from 2021, so demand is climbing while the candidacy math has not changed.
Starting the prescription layer from home in Florida
Florida law is more permissive on this than most patients expect. Florida Statutes section 456.47 provides that “if a telehealth provider conducts a patient evaluation sufficient to diagnose and treat the patient, the telehealth provider is not required to research a patient’s medical history or conduct a physical examination of the patient before using telehealth to provide health care services to the patient.”
The only prescribing prohibition in that statute is on Schedule II controlled substances, subject to 4 exceptions. Minoxidil and spironolactone are not controlled substances.
The standard of care still applies in full. A prescriber starting spironolactone without discussing pregnancy risk and potassium monitoring is cutting a corner the statute does not authorize, and the same evaluation requirement that makes telehealth prescribing legal is the requirement that makes a proper workup necessary.
Real Patient Results
Microneedling + PRF + Exosomes — After 2 Sessions
Results vary by individual and treatment plan
Who should see a dermatologist before booking anything
Some of the women reading this should not book a scalp appointment yet, here or anywhere.
See a dermatologist first if your hair loss started at the crown and your scalp is tender, tight, itchy, or burning.
That pattern raises the question of scarring alopecia, which may need a biopsy to identify. Nothing offered in a med spa helps a scarred follicle, and injecting into active scarring disease can do harm.
See a dermatologist first if you have round, well-defined bald patches.
That points toward alopecia areata, where 3 approved drugs exist and none of them is available here.
Wait if your hair came out suddenly and heavily 2 to 3 months after a delivery, a surgery, a fever, or a rapid weight change.
That pattern is usually telogen effluvium and it commonly resolves on its own once the trigger is addressed. A thyroid and iron workup comes before a treatment plan.
Reconsider the whole category if you want 1 treatment, once, and then to be done.
Pattern hair loss is managed indefinitely. If that is not something you want to take on, spending money on a partial version of it is the worst of the available options.
We would rather lose the appointment than take it for the wrong condition.
Frequently Asked Questions
Is there any treatment for women’s hair loss the FDA has actually approved?
One drug. Topical minoxidil, in the 2% solution and 5% foam strengths. No oral drug is approved for female pattern hair loss. Low-dose oral minoxidil and spironolactone are prescribed off-label, and low-level laser devices are FDA cleared, which is a lower regulatory bar than approved.
How do I know whether I have pattern loss or just shedding?
Timing and distribution. Pattern loss is gradual, concentrated at the part and crown, and the hairs get finer over years. Shedding is sudden and diffuse, usually starts 2 to 3 months after a trigger, and comes out in visible quantity. The 2 can happen at the same time, which is why the history matters more than the mirror.
Why does my face grow hair if the pill is for my scalp?
Oral minoxidil acts systemically, so it can stimulate hair anywhere. How common that is depends entirely on how it is measured: clinicians recorded it in 15.1% of 1,404 patients in a 2021 study, a 2025 pooled analysis put it at 23%, and when researchers telephoned 102 women in 2026 and asked directly, 71.6% reported it. Almost nobody stops over it. In the pooled data 0.49% discontinued for that reason, and in the 2026 survey 93.2% did not consider it a reason to stop.
My hair got worse after I started minoxidil. Should I quit?
Not on that basis alone, if you are inside the first 12 weeks. A temporary increase in shedding during that window is documented in the published literature and it settles. Raise it with your prescriber rather than stopping on your own.
Can I take finasteride the way my husband does?
No. Its FDA label reads “in MEN ONLY” and states it is not indicated for use in women. The label also instructs women who are or may be pregnant not to handle crushed or broken tablets.
Should I get my ferritin checked?
It is a reasonable test to ask for, and understand what the result does not tell you. There is an association in the literature between low ferritin and non-scarring hair loss in women, but there is no established target level for hair specifically, and no randomized trial has shown that iron supplementation regrows hair in women who are not anemic. A 2023 clinical review in Cutis notes it remains unclear whether supplementation improves hair density or caliber at all. The test is worth having. A number is not a treatment plan.
Does my postpartum shedding mean I have female pattern hair loss?
Usually not on its own. Shedding that begins 2 to 3 months after delivery is the classic pattern for telogen effluvium and it commonly resolves without treatment. What complicates it is that a shedding episode can reveal underlying pattern loss that was already progressing, which is why the assessment looks at the part width and hair calibre rather than only at how much is coming out.
Are exosomes worth the upgrade?
There are no FDA-approved exosome products for any indication. The FDA published a safety notification in 2019 after serious adverse events in Nebraska, and issued a warning letter in May 2025 to a company marketing exosomes for androgenetic alopecia, finding them to be unapproved new drugs and unlicensed biological products. Ask any clinic offering them whether the product has FDA approval for this use or is being administered under an investigational new drug application, and decide with the answer written down.
Am I a candidate for a hair transplant?
Statistically, probably not. The American Hair Loss Association estimates 2 to 5% of women with hair loss are potential surgical candidates, against approximately 90 percent of balding men, because female thinning is diffuse and the donor area is often thinning as well. The ISHRS 2025 census found strip harvesting used in 30.0% of female procedures against 12.5% of male ones, which reflects how much tighter the donor supply is in women. A surgeon who has not measured your donor area has not given you an opinion yet.
Can I be treated without coming in?
For the prescription layer, often yes, through a Florida-licensed prescriber. Florida Statutes section 456.47 permits a telehealth evaluation without a prior physical examination, and neither minoxidil nor spironolactone is a controlled substance. Revive 365 Wellness offers telehealth appointments for consultation, and does not prescribe hair-loss medication.
Book a consultation in Weston
Bring anything that helps establish a timeline: when the thinning started, what was happening 2 to 3 months before it, and photographs of your part from a year or 2 ago if you have them.
